Capital Advisors Ltd’s Regenxbio RGNX Stock Holding History

Capital Advisors Ltd’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-10	Closed	–	–	1514
2023 Q4	$0	Hold	10	–	–	﹤0.01%	1455
2023 Q3	$0	Buy	+10	New	+$181	﹤0.01%	1449

Other funds holding RGNX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Capital Advisors Ltd's RGNX Position: Q1 2024 in Review

Capital Advisors Ltd sold out of Regenxbio (RGNX) in Q1 2024, closing a stake of 10 shares.

Capital Advisors Ltd first reported a position in RGNX in Q3 2023 and held it in 2 quarters. The position peaked at $0 in Q4 2023. 188 funds tracked by Wall St. Rank hold RGNX as of Q1 2024.

Capital Advisors Ltd reported no remaining Regenxbio position as of Q1 2024 after selling out during the quarter.
Capital Advisors Ltd sold 10 Regenxbio shares in Q1 2024.
Capital Advisors Ltd first reported a position in Regenxbio in Q3 2023 and held it in 2 quarters.
Capital Advisors Ltd's Regenxbio position peaked at $0 in Q4 2023.
188 funds tracked by Wall St. Rank held Regenxbio as of Q1 2024.

Based on Capital Advisors Ltd's 13F filing for Q1 2024, filed 18 Apr 2024.